34167-66-3

Basic information

• Product Name: Imidazo[1,2-a]pyridine, 5,6,7,8-tetrahydro- (8CI,9CI)
• Synonyms: Imidazo[1,2-a]pyridine, 5,6,7,8-tetrahydro- (8CI,9CI);5,6,7,8-Tetrahydro-imidazo[1,2-a]pyridine;Imidazo[1,2-a]pyridine, 5,6,7,8-tetrahydro-
• CAS NO: 34167-66-3
• Molecular Formula: C₇H₁₀N₂
• Molecular Weight: 122.1677
• Product Categories: AMINETERTIARY
• Mol File: 34167-66-3.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 284.716 °C at 760 mmHg
• Flash Point: 125.992 °C
• Appearance: /
• Density: 1.181 g/cm³
• Vapor Pressure: 0.005mmHg at 25°C
• Refractive Index: 1.628
• PKA: 7.75±0.20(Predicted)
• CAS DataBase Reference: Imidazo[1,2-a]pyridine, 5,6,7,8-tetrahydro- (8CI,9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Imidazo[1,2-a]pyridine, 5,6,7,8-tetrahydro- (8CI,9CI)(34167-66-3)
• EPA Substance Registry System: Imidazo[1,2-a]pyridine, 5,6,7,8-tetrahydro- (8CI,9CI)(34167-66-3)

Safety Data

• Hazardous Substances Data: 34167-66-3(Hazardous Substances Data)

Usage

General Description

Imidazo[1,2-a]pyridine, 5,6,7,8-tetrahydro- (8CI,9CI) is a chemical compound falling under the class of Imidazo [1,2-a] pyridines, which are heterocyclic aromatic organic compounds consisting of a pyridine ring fused to an imidazole ring. Imidazo[1,2-a]pyridine, 5,6,7,8-tetrahydro- (8CI,9CI), in particular, is characterized by its tetrahydro structure, indicating the addition of four hydrogen atoms. The (8CI,9CI) identifies its specific isomer form. Imidazo[1,2-a]pyridine, 5,6,7,8-tetrahydro- (8CI,9CI) is often used in chemical research and can play a role in the development of pharmaceuticals, though its specific properties and uses may vary widely.

InChI:InChI=1/C7H10N2/c1-2-5-9-6-4-8-7(9)3-1/h4,6H,1-3,5H2

Upstream product

• 675-20-7 piperidin-2-one 
• 645-36-3 2,2-diethoxy-ethanamine 
• 137415-92-0 2-(4-chlorobutyl)imidazole 
• 191542-41-3 1-<4-(phenylselanyl)butyl>-2-tosyl-1H-imidazole 
• 6280-87-1 δ-chlorovaleronitrile 
• 77570-16-2 methyl 3-chlorobutanimidate hydrochloride 
• 274-76-0 imidazo[1,2-a]pyridine 

Downstream Products

• 156817-72-0 3-bromo-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine 

Relevant articles and documents

Bicyclic imidazolium-based ionic liquids: synthesis and characterization

We previously reported the use of imidazole as starting compound for preparing a bicyclic imidazolium ionic liquid, [b-3C-im][NTf2], with an overall 29% isolated yield in four synthetic steps. This new room temperature ionic liquid was shown to be far more chemically stable than commonly used [bmim][PF6], [bdmim][PF6], and [bdmim][NTf2]. Because of this intriguing chemical stability, it prompted us to develop a more generalized and high yielding synthesis so that molecular diversity of bicyclic ionic liquids may be explored. In this work, we amended the previous synthetic route by employing 4-chlorobutyronitrile or 5-chlorovaleronitrile as starting materials and successfully developed a five-step synthesis of a series of novel bicyclic imidazolium-based ionic liquids in 40-53% overall isolated yields. We investigated intrinsic reactivity of all bicyclic ionic liquids prepared and found that, under strongly basic conditions, among all tested ionic liquids the 5,5-membered [R-3C-im][NTf2] ionic liquids were most stable to solvent deuterium isotope exchange while the previously reported [bdmim][NTf2] ionic liquid was 50% deuterium exchanged at its C-2 methyl in 30 min at ambient temperature. Under identical condition, the commonly used [bmim][NTf2] ionic liquid was deuterium exchanged instantaneously at its C-2 hydrogen. In the absence of bases, only [bmim][PF6] was deuterium exchanged (50% within 1 h) and all other ionic liquids gave no detectable exchanges even after 25 days at ambient temperature. Moreover, both [bmim][NTf2] and [bdmim][NTf2] ionic liquids were readily methylated at C-2 position with methyl iodide under basic condition at room temperature. Under the same condition, [R-3C-im][NTf2] and [R-4C-im][NTf2] ionic liquids were completely stable and chemically inert. We envisioned that [R-3C-im][NTf2] should be well suited as solvents for organic synthesis.

ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS

Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors of Factor D described herein reduce the excessive activation of complement.

Expedient synthesis of substituted imidazoles from nitriles

Expedient and practical new methodology for the synthesis of substituted imidazoles was developed to provide a rapid access to a variety of 2-substituted, 1,2-disubstituted and 1,2,4-trisubstituted imidazoles by the direct CuCl-mediated reaction of nitriles with α-amino acetals in an intermolecular as well as intramolecular fashion.